by Greg B. Scott, Executive Editor
January 10, 2013 -- The annual pilgrimage to San Francisco to attend what is affectionately known as just “JPMorgan” is now over. After four or five grueling days of back-to-back 30-minute meetings, I can report that interest in China is very high. Most companies included a China Strategy in their presentations, as investors are demanding to know how their portfolio companies are going to address the world’s third largest, soon to be second largest, global market. For any China life science company wishing to export to the West, or US/European company that is looking to leverage China’s 22% market growth, JPMorgan is a must-attend event. More details....
